SYNAGIS

LOE ApproachingmAb

palivizumab

BLAINTRAMUSCULARVIALPriority Review
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14

Mechanism of Action

Fusion Protein Inhibitors

Pharmacologic Class:

Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

Clinical Trials (5)

NCT06851806N/ANot Yet Recruiting

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Started Nov 2025
138 enrolled
Respiratory Syncytial Virus (RSV)
NCT05121246Phase 1Completed

A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.

Started Jun 2022
150 enrolled
Healthy Volunteers
NCT04540627Phase 1Completed

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

Started Jul 2020
56 enrolled
Healthy Adult Participants
NCT02968173Phase 3Completed

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

Started Nov 2016
50 enrolled
Respiratory Syncytial Virus (RSV)
NCT02282982N/ACompleted

Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

Started Oct 2014
359 enrolled
Respiratory Syncytial Virus (RSV)